


Quest Diagnostics Inc. (DGX)

NYSE; healthcare; SIC 8071, Services-Medical Laboratories; CIK 0001022079

Quest Diagnostics Inc. DGX; healthcare	
Grade	D A B C D E fourth fifth of 371 graded peers percentile 77.3; sampling error 2.5 points; lower is stronger
Rank	287 of 371
Profitability	C percentile 49.9
Solvency	D percentile 73.4
Growth and financing	C percentile 50.8
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$16.2B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	11 of 14
Graded from	filings received through Feb 26, 2026 225 days before the rescans; latest periodic filing 10-Q received Jul 23, 2026
Last close	\$230.78 2026-10-08; market equity \$25.5B
Price used in grade	None



D, the sloth

fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: E from Feb 21, 2026, D from Mar 21, 2026, D/E from Jun 21, 2026, D from Aug 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. In the right hands and with the right context,

our diagnostic insights can inspire actions that transform lives and create a healthier world.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 49.9						
Gross profitability		22.6%	32.2%	59.6	372	2025-12-31
Return on invested capital		10.0%	9.3%	41.1	74	2025-12-31
Accruals ratio		(5.5%)	(6.6%)	59.4	811	2025-12-31
Gross margin stability, five years		2.3 pts	2.8 pts	39.7	243	2025-12-31
Solvency, sleeve percentile 73.4						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		not computable	(0.31)			one or more required annual facts are missing
Net debt to EBITDA		2.23x	1.82x	58.1	75	2025-12-31
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		1.04x	2.96x	88.7	839	2025-12-31
Growth and financing, sleeve percentile 50.8						
Revenue growth, three-year compound		3.7%	10.0%	62.3	415	2025-12-31
Free cash flow growth, three-year compound		1.1%	10.9%	71.6	96	2025-12-31
Reinvestment rate		(14.0%)	37.1%	76.7	104	2025-12-31
Asset growth, three years		8.1%	2.1%	34.3	704	2025-12-31
Net share issuance, one year		(1.0%)	2.5%	9.2	634	2026-02-02

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
282	Abeona Therapeutics Inc. (ABEO)	75.9	D	fortress balance sheet
283	Cytosorbents Corp. (CTSO)	76.2	D	short runway, fortress balance sheet

284	Tilray Brands, Inc. (TLRY)	76.5	D	fortress balance sheet
285	Baxter International Inc. (BAX)	76.8	D	
286	Vivos Therapeutics, Inc. (VIVOS)	77.0	D	dilution, short runway, late filer
287	Quest Diagnostics Inc. (DGX) <	77.3	D	
288	biote Corp. (BTMD)	77.6	D/E	
289	Protalix BioTherapeutics, Inc. (PLX)	77.8	D/E	
290	Femasys Inc. (FEMY)	78.1	D/E	dilution, short runway
291	X4 Pharmaceuticals, Inc. (XFOR)	78.4	D/E	dilution, fortress balance sheet
292	Milestone Scientific Inc. (MLSS)	78.6	D/E	late filer

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	28.3%	8.0%	64
Distance from 52-week high	(6.7%)	(31.4%)	91
EBIT to enterprise value	5.1%	(1.5%)	79
Free cash flow yield	5.3%	(1.0%)	83
Book value to price	0.30	0.28	51
Sales to price	0.43	0.31	62
Composite equity issuance, five years	(29.7%)	20.3%	3
Relative strength against the sector, log excess return	0.04	(0.14)	64

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$626.0M
Operating cash flow, four quarters	\$1.9B
Months of runway	not finite
Days since last periodic filing	78 (10-Q received Jul 23, 2026)
Median daily dollar volume, 63 sessions	\$219.3M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$11.0B	2025-12-31	2026-02-26	10-K	0001022079-26-000015
2	cost of revenue	us-gaap:CostOfRevenue	\$7.4B	2025-12-31	2026-02-26	10-K	0001022079-26-000015
3	assets	us-gaap:Assets	\$16.2B	2025-12-31	2026-02-26	10-K	0001022079-26-000015
4	operating income	us-gaap:OperatingIncomeLoss	\$1.6B	2025-12-31	2026-02-26	10-K	0001022079-26-000015
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndRelatedIncome	\$1.3B	2025-12-31	2026-02-26	10-K	0001022079-26-000015
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$314.0M	2025-12-31	2026-02-26	10-K	0001022079-26-000015

7	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$5.2B	2025-12-31	2026-02-26	10-K	0001022079-26-000015
8	book equity	us-gaap:StockholdersEquity	\$7.2B	2025-12-31	2026-02-26	10-K	0001022079-26-000015
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$420.0M	2025-12-31	2026-02-26	10-K	0001022079-26-000015
10	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$5.6B	2024-12-31	2026-02-26	10-K	0001022079-26-000015
11	book equity	us-gaap:StockholdersEquity	\$6.8B	2024-12-31	2026-02-26	10-K	0001022079-26-000015
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$549.0M	2024-12-31	2026-02-26	10-K	0001022079-26-000015
13	net income	us-gaap:NetIncomeLoss	\$992.0M	2025-12-31	2026-02-26	10-K	0001022079-26-000015
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.9B	2025-12-31	2026-02-26	10-K	0001022079-26-000015
15	assets	us-gaap:Assets	\$16.2B	2024-12-31	2026-02-26	10-K	0001022079-26-000015
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$9.9B	2024-12-31	2026-02-26	10-K	0001022079-26-000015
17	cost of revenue	us-gaap:CostOfRevenue	\$6.6B	2024-12-31	2026-02-26	10-K	0001022079-26-000015
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$9.3B	2023-12-31	2026-02-26	10-K	0001022079-26-000015
19	cost of revenue	us-gaap:CostOfRevenue	\$6.2B	2023-12-31	2026-02-26	10-K	0001022079-26-000015
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$9.9B	2022-12-31	2025-02-20	10-K	0001022079-25-000044
21	cost of revenue	us-gaap:CostOfRevenue	\$6.5B	2022-12-31	2025-02-20	10-K	0001022079-25-000044
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$10.8B	2021-12-31	2024-02-22	10-K	0001022079-24-000041
23	cost of revenue	us-gaap:CostOfRevenue	\$6.6B	2021-12-31	2024-02-22	10-K	0001022079-24-000041
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$570.0M	2025-12-31	2026-02-26	10-K	0001022079-26-000015
25	operating income	us-gaap:OperatingIncomeLoss	\$1.3B	2023-12-31	2026-02-26	10-K	0001022079-26-000015
26	interest expense	us-gaap:InterestExpense	\$163.0M	2023-12-31	2024-02-22	10-K	0001022079-24-000041
27	current assets	us-gaap:AssetsCurrent	\$2.4B	2025-12-31	2026-02-26	10-K	0001022079-26-000015
28	current liabilities	us-gaap:LiabilitiesCurrent	\$2.3B	2025-12-31	2026-02-26	10-K	0001022079-26-000015
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$527.0M	2025-12-31	2026-02-26	10-K	0001022079-26-000015
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.3B	2024-12-31	2026-02-26	10-K	0001022079-26-000015
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$425.0M	2024-12-31	2026-02-26	10-K	0001022079-26-000015
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.3B	2023-12-31	2026-02-26	10-K	0001022079-26-000015
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$408.0M	2023-12-31	2026-02-26	10-K	0001022079-26-000015
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.7B	2022-12-31	2025-02-20	10-K	0001022079-25-000044
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$404.0M	2022-12-31	2025-02-20	10-K	0001022079-25-000044
36	current assets	us-gaap:AssetsCurrent	\$2.4B	2024-12-31	2026-02-26	10-K	0001022079-26-000015
37	current liabilities	us-gaap:LiabilitiesCurrent	\$2.2B	2024-12-31	2026-02-26	10-K	0001022079-26-000015
38	assets	us-gaap:Assets	\$14.0B	2023-12-31	2025-02-20	10-K	0001022079-25-000044
39	assets	us-gaap:Assets	\$12.8B	2022-12-31	2024-02-22	10-K	0001022079-24-000041
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	109,866,320	2026-02-02	2026-02-26	10-K	0001022079-26-000015
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	110,978,069	2025-01-31	2025-02-20	10-K	0001022079-25-000044